Hepatocellular adenoma surgery: Difference between revisions
Jump to navigation
Jump to search
| Line 40: | Line 40: | ||
| pmid = 8472159 | | pmid = 8472159 | ||
}}</ref> | }}</ref> | ||
* The liver transplantation may be considered for patients of hepatocellular adenoma associated with glycogen storage disease type1. | * The liver transplantation may be considered for patients of hepatocellular adenoma associated with glycogen storage disease type1.<ref>{{Cite journal | ||
| author = [[Jan P. Lerut]], [[Olga Ciccarelli]], [[Christine Sempoux]], [[Etienne Danse]], [[Jacques deFlandre]], [[Yves Horsmans]], [[Etienne Sokal]] & [[Jean-Bernard Otte]] | |||
| title = Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation | |||
| journal = [[Transplant international : official journal of the European Society for Organ Transplantation]] | |||
| volume = 16 | |||
| issue = 12 | |||
| pages = 879–884 | |||
| year = 2003 | |||
| month = December | |||
| doi = 10.1007/s00147-003-0613-3 | |||
| pmid = 12904843 | |||
}}</ref> | |||
* The adenoma patients who are poor candidates for surgery (centrally located lesions, multiple adenomas, morbid obesity), radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered. | * The adenoma patients who are poor candidates for surgery (centrally located lesions, multiple adenomas, morbid obesity), radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered. | ||
* Radiofrequency ablation (RFA) is a minimally invasive technique that can be used for hepaocellular adenomas, hepatocellular carcinoma and colorectal metastases as well.<ref>{{Cite journal | * Radiofrequency ablation (RFA) is a minimally invasive technique that can be used for hepaocellular adenomas, hepatocellular carcinoma and colorectal metastases as well.<ref>{{Cite journal | ||
Revision as of 16:15, 11 January 2019
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma surgery On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma surgery |
|
Risk calculators and risk factors for Hepatocellular adenoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Zahir Ali Shaikh, MD[3]
Overview
There is no specific medical therapy for the hepatocellular adenomas. The wait and watch policy is recommended for hepatocellular adenoams <5cm following cessation of offending drugs (OCPs) and no further growth detected. Annual followup is scheduled with MRI or ultrasound until menopause.
Hepatocellular adenoma surgery
- Surgery is the treatment of choice for hepatocellular adenoma, as it can achieved in a controlled and safe manner.[1][2][3]
- Elective surgical resection of hepatocellular adenoma is considered for; all adenoma lesions >5cm in diameter, lesions that increase in size, lesions with intratumoral hemorrhage and male patients (irrespective of adenoma size).[4][5]
- The liver transplantation may be considered for patients of hepatocellular adenoma associated with glycogen storage disease type1.[6]
- The adenoma patients who are poor candidates for surgery (centrally located lesions, multiple adenomas, morbid obesity), radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered.
- Radiofrequency ablation (RFA) is a minimally invasive technique that can be used for hepaocellular adenomas, hepatocellular carcinoma and colorectal metastases as well.[7]
- Transcatheter arterial embolization (TAE) is used in adenoma patients with hemodynamic instability due to bleeding hypervascular arterial lesions.
- The algorithm approach to management of hepatocellular adenoma based on clinical features, gender, imaging and histology.
| MRI features of hepatic adenoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Asymptomatic | Symptomatic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Male & glycogen storage disease | Female | Hemodynamically stable | Hemodynamically unstable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Resection irrespective of size & sybtype | Stop offending drugs | Radiofrequency ablation resection | Embolization resection | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <5cm | >5cm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Steatotic (HNF1 a) Hepatic adenoma | Inflammatory hepatic adenoma | Beta catenin hepatic adenoma | Otehrs | Consider resection | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Followup, genetic counselling for MODY & hepatic adenomatosis | Close followup, treatment of obesity & discontinue obesity | Biopsy & resection if confirmed | Biopsy & treat based on subtype | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Paulette Bioulac-Sage, Herve Laumonier, Gabrielle Couchy, Brigitte Le Bail, Antonio Sa Cunha, Anne Rullier, Christophe Laurent, Jean-Frederic Blanc, Gaelle Cubel, Herve Trillaud, Jessica Zucman-Rossi, Charles Balabaud & Jean Saric (2009). "Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience". Hepatology (Baltimore, Md.). 50 (2): 481–489. doi:10.1002/hep.22995. PMID 19585623. Unknown parameter
|month=ignored (help) - ↑ Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G (2005). "Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors". World J Gastroenterol. 11 (36): 5691–5. PMID 16237767.Full text
- ↑ Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC (1996). "Selective management of hepatic adenomas". Am Surg. 62 (10): 825–9. PMID 8813164.
- ↑ T. Terkivatan, J. H. de Wilt, R. A. de Man, R. R. van Rijn, H. W. Tilanus & J. N. IJzermans (2001). "Treatment of ruptured hepatocellular adenoma". The British journal of surgery. 88 (2): 207–209. doi:10.1046/j.1365-2168.2001.01648.x. PMID 11167868. Unknown parameter
|month=ignored (help) - ↑ J. Belghiti, D. Pateron, Y. Panis, V. Vilgrain, J. F. Flejou, J. P. Benhamou & F. Fekete (1993). "Resection of presumed benign liver tumours". The British journal of surgery. 80 (3): 380–383. PMID 8472159. Unknown parameter
|month=ignored (help) - ↑ Jan P. Lerut, Olga Ciccarelli, Christine Sempoux, Etienne Danse, Jacques deFlandre, Yves Horsmans, Etienne Sokal & Jean-Bernard Otte (2003). "Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation". Transplant international : official journal of the European Society for Organ Transplantation. 16 (12): 879–884. doi:10.1007/s00147-003-0613-3. PMID 12904843. Unknown parameter
|month=ignored (help) - ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=ignored (help)